acute hypoxia after blood transfusion Acute hypoxia after blood transfusion
Conditions
Interventions
Blood collection form an artery line. 
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult ICU patients: - ICU patients who receive a transfusion without lung injury - ICU patients who receive a transfusion and have indirect ARDS (e.g. due to pancreatitis, trauma, etc), - ICU patients who receive a transfusion and have infectious pneumonia - ICU patients without transfusion and with non-pulmonary indirect ARDS - ICU patients without transfusion and with infectious pneumonia - Healthy volunteers recruited through Sanquin*s donor system
Exclusion criteria
Exclusion criteria: Patients with objection to registration of data for scientific use as noted in the patient file Patient in whom it is impossible to obtain blood samples Patients with massive haemorrhage Patients with ARDS due to multiple transfusionsPatients with Extra corporal membrane oxygenationPatients with a high viral load of Human Immunodeficiency Virus or other bloodborne infections
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint of this study is to identify TRALI-specific biomarkers by comparing plasma proteomic profiles between the following groups: TRALI patients, indirect ARDS patients (with and without transfusion), pneumonia patients (with and without transfusion), and healthy volunteers. To isolate the impact of transfusion on the proteome and differentiate it from TRALI-specific changes, we will also analyze proteomic profiles before and after transfusion in relevant groups. This approach aims to increase the specificity and sensitivity of identified protein biomarkers for accurate TRALI diagnosis and facilitate the development of novel diagnostic assays. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secundary outcomes of this study are: 1) Characterizing the TRALI Proteome: we will perform in-depth characterization of the proteome in TRALI patients to gain a comprehensive understanding of the molecular mechanisms underlying TRALI pathophysiology. This analysis aims to uncover potential therapeutic targets and pathways involved in TRALI development. 2) Investigating Neutrophil and Treg responses: we will investigate the phenotype, activation status, and functional responses of neutrophils, Tregs and the complement system in TRALI patients compared to relevant control groups. This detailed analysis will shed light on the roles of neutrophils and Tregs in TRALI pathogenesis. | — |
Countries
Netherlands
Contacts
Public ContactA.P.J. Vlaar
Amsterdam UMC
Outcome results
None listed